LONDON, March 15 (Reuters) - Eli Lilly and Co. has withdrawn is application for approval to sell experimental eye drug Arxxant in Europe, two days after a similar regulatory setback for the product in the United States.
LONDON, March 15 (Reuters) - Eli Lilly and Co. has withdrawn is application for approval to sell experimental eye drug Arxxant in Europe, two days after a similar regulatory setback for the product in the United States.
